C4 Therapeutics Completes Phase 1 Trial Enrollment

An update from C4 Therapeutics ( (CCCC) ) is now available.

On August 7, 2025, C4 Therapeutics announced the completion of enrollment and dose escalation for its Phase 1 trial of cemsidomide in multiple myeloma (MM) and non-Hodgkin’s lymphoma (NHL), showing promising response rates. The company plans to align with the FDA on a Phase 2 dose by the end of 2025 and initiate registrational development in early 2026, focusing on MM treatment. Financially, C4T reported a decrease in revenue for Q2 2025 compared to the previous year, primarily due to a previous milestone payment, but maintained a strong cash position expected to fund operations until mid-2027.

The most recent analyst rating on (CCCC) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on C4 Therapeutics stock, see the CCCC Stock Forecast page.

Spark’s Take on CCCC Stock

According to Spark, TipRanks’ AI Analyst, CCCC is a Neutral.

The overall score of 52 reflects the significant financial challenges faced by C4 Therapeutics, including persistent losses and cash flow issues. Despite a stable balance sheet, the negative P/E ratio signals valuation concerns. Technical indicators suggest a potential recovery, but the high beta indicates considerable volatility, warranting caution.

To see Spark’s full report on CCCC stock, click here.

More about C4 Therapeutics

C4 Therapeutics (C4T) is a clinical-stage biopharmaceutical company focused on advancing targeted protein degradation science to develop new medicines for difficult-to-treat diseases. The company leverages its TORPEDO® platform to design small-molecule medicines aimed at degrading disease-causing proteins, particularly in oncology.

Average Trading Volume: 1,291,847

Technical Sentiment Signal: Sell

Current Market Cap: $142.7M

Find detailed analytics on CCCC stock on TipRanks’ Stock Analysis page.